Flossbach Von Storch SE Takes $955.58 Million Position in Thermo Fisher Scientific Inc. $TMO

Flossbach Von Storch SE purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,905,975 shares of the medical research company’s stock, valued at approximately $955,580,000. Thermo Fisher Scientific comprises 4.3% of Flossbach Von Storch SE’s portfolio, making the stock its 7th largest holding. Flossbach Von Storch SE owned 0.52% of Thermo Fisher Scientific at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in shares of Thermo Fisher Scientific by 0.9% in the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company’s stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP lifted its holdings in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company’s stock valued at $18,258,082,000 after buying an additional 31,455,105 shares during the period. BlackRock Inc. bought a new position in Thermo Fisher Scientific in the second quarter valued at approximately $15,501,867,000. State Street Corp grew its holdings in Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company’s stock worth $9,633,991,000 after acquiring an additional 229,630 shares during the period. Finally, Capital World Investors raised its position in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company’s stock valued at $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. 89.23% of the stock is owned by institutional investors.

Thermo Fisher Scientific Trading Up 4.3%

NYSE TMO opened at $614.32 on Thursday. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $227.14 billion, a P/E ratio of 33.05, a P/E/G ratio of 2.40 and a beta of 0.85. The stock’s 50-day moving average is $536.26 and its 200-day moving average is $508.51.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to analysts’ expectations of $11.71 billion. During the same period in the prior year, the business earned $4.28 EPS. Thermo Fisher Scientific’s revenue for the quarter was up 10.5% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.11%.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 420 shares of the stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This represents a 12.40% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total transaction of $5,744,700.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares of the company’s stock, valued at $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 52,053 shares of company stock worth $30,643,589 in the last three months. 0.33% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on TMO shares. HSBC cut Thermo Fisher Scientific from a “buy” rating to a “hold” rating and decreased their price objective for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Wells Fargo & Company lowered their price target on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, July 14th. Morgan Stanley boosted their price objective on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $619.41.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.